Straits Times Index
3,345.49 +6.55 (+0.20%) Nikkei
38,402.54 -434.92 (-1.12%) Hang Seng
18,512.19 +68.08 (+0.37%) FTSE 100
8,232.04 -30.71 (-0.37%) Bitcoin USD
70,935.13 +2,101.41 (+3.05%) CMC Crypto 200
1,478.47 +4.73 (+0.32%)
Connect Biopharma Holdings Limited (CNTB)
| Previous close | 1.7000 |
| Open | 1.5500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.4520 - 1.7500 |
| 52-week range | 0.5350 - 2.8400 |
| Volume | |
| Avg. volume | 118,422 |
| Market cap | 90.369M |
| Beta (5Y monthly) | -0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024 SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or t
- GlobeNewswire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-break
- GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD)Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asthma have been scheduled with the U.S. Food and Drug Administration (FDA) in Q2 2024 to discuss trial results and proposed registrational programsGranted Simcere the exclusive rights to develop, manufacture, and comme
